Murakami Takashi, Cardones Adela R, Finkelstein Steven E, Restifo Nicholas P, Klaunberg Brenda A, Nestle Frank O, Castillo S Sianna, Dennis Phillip A, Hwang Sam T
Dermatology Branch, CCR, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Exp Med. 2003 Nov 3;198(9):1337-47. doi: 10.1084/jem.20030593. Epub 2003 Oct 27.
Human melanoma cells frequently express CC chemokine receptor (CCR)10, a receptor whose ligand (CCL27) is constitutively produced by keratinocytes. Compared with B16 murine melanoma, cells rendered more immunogenic via overexpression of luciferase, B16 cells that overexpressed both luciferase and CCR10 resisted host immune responses and readily formed tumors. In vitro, exposure of tumor cells to CCL27 led to rapid activation of Akt, resistance to cell death induced by melanoma antigen-specific cytotoxic T cells, and phosphatidylinositol-3-kinase (PI3K)-dependent protection from apoptosis induced by Fas cross-linking. In vivo, cutaneous injection of neutralizing antibodies to endogenous CCL27 blocked growth of CCR10-expressing melanoma cells. We propose that CCR10 engagement by locally produced CCL27 allows melanoma cells to escape host immune antitumor killing mechanisms (possibly through activation of PI3K/Akt), thereby providing a means for tumor progression.
人类黑色素瘤细胞经常表达CC趋化因子受体(CCR)10,其配体(CCL27)由角质形成细胞组成性产生。与通过荧光素酶过表达而具有更强免疫原性的B16小鼠黑色素瘤细胞相比,同时过表达荧光素酶和CCR10的B16细胞能够抵抗宿主免疫反应并易于形成肿瘤。在体外,将肿瘤细胞暴露于CCL27会导致Akt迅速激活、对黑色素瘤抗原特异性细胞毒性T细胞诱导的细胞死亡产生抗性以及对Fas交联诱导的凋亡产生磷脂酰肌醇-3-激酶(PI3K)依赖性保护。在体内,向皮肤注射针对内源性CCL27的中和抗体可阻断表达CCR10的黑色素瘤细胞的生长。我们提出,局部产生的CCL27与CCR10结合可使黑色素瘤细胞逃避宿主免疫抗肿瘤杀伤机制(可能是通过激活PI3K/Akt),从而为肿瘤进展提供一种途径。